aromatase inhibitors in disclosures male...
TRANSCRIPT
10/27/2017
1
Aromatase Inhibitors in Male Infertility: The hype of hypogonadism?BEATRIZ UGALDE, PHARM.D.
H-E-B/UNIVERSITY OF TEXAS COMMUNITY PHARMACY PGY1
03 NOVEMBER 2017
PHARMACOTHERAPY ROUNDS
DisclosuresNo conflicts of interest to disclose
2
Objectives•Describe adult male infertility and hypogonadism•Review the role of androgens in spermatogenesis•Outline current management strategies•Assess use of aromatase inhibitors in male infertility treatment•Recommend plan for patients with hypogonadism and infertility
3
Infertility1-5
•Inability of a couple to achieve pregnancy despite unprotected intercourse after 12 months•Affects 6.1 million couples in the United States• 10% reproductive aged adult• 15% of couples trying to conceive
•Male factor contributes to 50% of all cases •20% cases solely due to male factor
4
Common Terms in Male Infertility1,4,6,7
•Anorchia – Absence of both testes at birth•Azoospermia – complete or near lack of sperm production•Cryptozoospermia – type of azoospermia in which there is small amount of sperm only detected by centrifugation and concentration of the sample•Cryptorchidism – condition in which testicles have not descended•Oligospermia – Low sperm count <15 million spermatozoa/mL•Varicocele – Enlargement of veins in the scrotum
5APPENDIX A
Male Infertility1,3-5,8
•50-60% of these men have an identifiable cause•40-50% idiopathic•20% of men diagnosed with an endocrine problem•One-third of men have oligospermia or azoospermia• 43% of oligospermic due to hypoandrogenism• 45% azoospermic men due to spermatogenic dysfunction
•Degree of infertility variable and dependent on individual patient
6
10/27/2017
2
Why is this important?1,3,8,9
•Male partner factors are often neglected• High pregnancy rates with assisted reproductive techniques (ART)
•Area for improvement in current practice• Can often be reversed/cured• Risk of overlooking serious condition• ART can extensive and expensive and dangerous to mother and child• Treatment with medication cheaper than ART• Medications cost around $912 • In vitro fertilization: $19,324 for first cycle + $6955 per additional cycle• Many insurances do not cover fertility treatment
7
Knowledge CheckMultiple choice:What percent of cases have some sort of male factor involvement?A. 20%B. 30%C. 50%D. 70%
8
Diagnosis of male infertility4,7,10
•Medical history and physical examination• Involve urologist or specialist• Scrotal ultrasound• At least 2 semen analyses• Limits based on WHO criteria (Appendix B)• Abnormal sperm motility, morphology, and concentration
•Comprehensive andrological examination• If at least 2 abnormal semen analyses• Include testosterone and follicle stimulating hormone
9
Causes of male infertility1
10
Pre-testicular Testicular Post-testicular
Hypothalamic pituitary disorder Varicocele Ductular obstruction/scarring
Thyroid Disorder Trauma Retrograde ejaculation
Adrenal Disorder Infection Antibodies to sperm or seminal plasma
Drugs Drugs/Toxins Developmental abnormalities
Chromosomal abnormalities Androgen insensitivity
Developmental abnormalities Poor coital technique
Defective androgen production Sexual dysfunction, impotence
Idiopathic
Androgens and spermatogenesis
11
Bhasin et al. Harrison’s principles of internal med. 2015
Spermatogenesis1,6
•Testosterone (T) production and spermatogenesis controlled by the hypothalamic axis•Hypothalamus releases Gonadotropin releasing hormone (GnRH)• Pulsatile
•Stimulates anterior pituitary to secrete gonadotropins• Luteinizing hormone (LH)• Follicle stimulating hormone (FSH)
12
Bhasin et al. Harrison’s principles of internal med. 2015
APPENDIX C
10/27/2017
3
Spermatogenesis1,6
•FSH stimulates Sertoli cells • Production of paracrine growth factor • Support sperm growth
• Production of androgen binding globulin
•LH stimulates Leydig Cells• T produced• Binds to androgen binding globulin
• Secreted into seminiferous tubules and circulation
13
Bhasin et al. Harrison’s principles of internal med. 2015
APPENDIX C
T role in Spermatogenesis1
•T in seminiferous tubules are 80-100x more concentrated than in the general circulation• High concentration necessary for sperm production• Binds to androgen receptors
• Spermatogenesis in Sertoli cells• Inhibition of germ cell apoptosis
•T in the circulation provides negative feedback at hypothalamus and pituitary• GnRH, LH, FSH secretion
•T converted to estradiol (E2)• Aromatase: found in testes, prostate, bone, brain, adipose• E2 also provides negative feedback
14
Fode et al. Pathophysiology of disease. 2014
APPENDIX D
Importance of Estrogen and Aromatase11
•Effects growth, development, and function of Leydig cells•Promotes maturation of spermatogonia•Paracrine function: inhibits aromatase activity in Sertoli cells•Autocrine function: low levels inhibit germ cell apoptosis•Lack of aromatase leads to impaired spermatogenesis
15
Detrimental effects of Estrogen11
•Negative feedback on Hypothalamus-pituitary axis• ↓ FSH and ↓ LH Æ↓ spermatogenesis
•Inhibits spermiogenesis related genes and promotes spermatocyte apoptosis•Inhibitory effects on Sertoli and Leydig cell functions•Careful regulation needed for spermatogenesis
16
Knowledge CheckMultiple choice:Aromatase is found in which of the following tissues?A. TestesB. BrainC. AdiposeD. Two of the aboveE. All of the above
17
Hypogonadism
18
10/27/2017
4
Hypogonadism Etiology1,4
•Primary: • Testicular failure• Hypergonadotropic hypogonadism (HerH)
•Secondary• Hypothalamus-Pituitary Axis failure• Hypogonadotropic hypogonadism (HoH)
19
Hypergonadotropic Hypogonadism1,4,5,12
•Characterized by:• ↑ FSH and/or LH• Leydig cell dysfunction
•Low T (< 300 ng/dL) and associated symptoms• ↓ libido, poor erections, hot flashes, low energy, weight gain, mood
change, sleep disturbance, ↓ body hair, infertility
•Deficient spermatogenesis
20
HerH Etiology1,4
•Genetic•Testicular tumor•Trauma•Varicocele•Systemic diseases (liver cirrhosis, renal failure)•Iatrogenic: Surgery, radiotherapy, medications
21
Hypogonadotropic Hypogonadism1,4,5,12
•Uncommon cause of male infertility•Characterized by either• ↓ GnRH production Æ↓ FSH and/or LH• Rare disorders of the pituitary (normal GnRH levels)• Result in primary deficiencies of FSH and LH
•Low T and associated symptoms•Deficient spermatogenesis
22
HoH Etiology1,4
•Genetic• Abnormal synthesis/release GnRH (idiopathic)• Kallmann syndrome - failed GnRH axonal migration in fetal development• GnRH receptor abnormalities
•Pituitary mass lesions•Hyperprolactinemia•Anabolic steroid use•Radiotherapy•Obesity
23
Current treatment strategies• TH E OPTIMAL E VALUATION OF TH E INFE RTILE MALE :
AME RICAN UROLOGY ASSOCIATION BE ST PRACTICE STATE ME NT.
• E UROPE AN ASSOCIATION OF UROLOGY GUIDE L INE S ON MALE INFE RTIL ITY.
24
10/27/2017
5
European Association of Urology Guideline-Based Treatment for hypogonadism4
•Provide T replacement for symptomatic patients with primary and secondary hypogonadism•In men with hypogonadotropic hypogonadism, induce spermatogenesis by an effective drug therapy (Human chorionic gonadotropin)•Do not use T replacement for the treatment of male infertility
25
Treatment of Idiopathic Hypogonadism1,4
•Assisted reproductive treatment•Empirical medical treatment• Gonadotropin• Human chorionic gonadotropin (hCG) ± follicle stimulating hormone (FSH)
• Selective Estrogen Receptor Modulators (SERMs)• Clomiphene• Tamoxifen
• Aromatase Inhibitors• Anastrozole• Letrozole
•Lifestyle changes
26
APPENDIX E 27
hCG
Rambhatla et al. Urol. 2016
Human Chorionic Gonadotropin14,15
•Mechanism of action:• Has the bioactivity of LH
•Labeled use:• Hypogonadotropic hypogonadism• Ovulation induction• Prepubertal cryptorchidism
•Off label use:• Spermatogenesis induction in hypogonadism
28
Clinical Pharmacology
Human Chorionic Gonadotropin14,15
•Dose: IM injection• HH• 500-1000 units 3 times weekly for 3 weeks, then 2 times weekly for 3 weeks• 4000 units 3 times weekly for 6-9 months, then 2000 units 3 times weekly for 3
months• Spermatogenesis in idiopathic HH (off-label)• 1000-2000 units 2-3 times weekly until T levels normal (2-3 months)• May then add FSH if needed to induce spermatogenesis• Continue hCG dose required to maintain T levels
29
Human Chorionic Gonadotropin5,14,15
•Side Effects• Elevated liver enzymes• Gynecomastia• Injection site reaction• Mood changes
30
10/27/2017
6
Human Chorionic Gonadotropin2,5,14,15
•Pros:• Approved for treatment of hypogonadotropic hypogonadism
•Cons:• High cost• Invasive
•Clinical use• Usually recommended if failed clomiphene or anastrozole
31
Selective Estrogen Receptor Modulators13-15
•MOA: block negative feedback at hypothalamus and pituitary and indirectly enhance LH and FSH secretion•Most studied oral drugs in male infertility•Drugs:• Clomiphene• Tamoxifen
32
Clomiphene citrate3,13-15
•Labeled use:• Infertility in women
•Off-label use:• Idiopathic oligospermia associated infertility
•Dose:• Optimal dosing not established: 12.5-400 mg/day• Common: • 25 mg 3 times weekly or once daily• 50 mg every other day up to once daily
33
Clinical Pharmacology
Clomiphene citrate5,13-15
•Side effects• Hot flashes• Headache• Nausea/Vomiting• Weight gain• Gynecomastia• Visual disturbances
34
Clomiphene citrate2,3,5,13-15
•Pros:• Can ↑ FSH and LH• Inexpensive• Well tolerated• Most evidence• Longer duration in studies (15 months)
•Cons:• Can ↑ E2• May not be best in patients with elevated FSH• May worsen semen parameters
•Clinical Use: • Low testosterone and symptoms of low testosterone in male infertility
35
Aromatase inhibitors2,3
•MOA: inhibit aromatase and ↓E2• May lead to stronger GnRH pulses and ↑FSH
•Drugs• Steroidal – irreversible• Testolactone• Formestane• Exemestane
• Nonsteroidal – reversible• Letrozole• Anastrozole
36
10/27/2017
7
Aromatase inhibitors13-15
•Labeled use:• Breast cancer
•Off label use:• Delayed puberty• Endometriosis• Infertility
•Dose:• Letrozole 2.5 mg daily• Anastrozole 1 mg daily• In practice: ½ – 1 tablet 2-3 times weekly
37
Clinical Pharmacology
Aromatase inhibitors13-15
•Half-life:• Letrozole: 48 hours• Anastrozole: 50 hours
•Side effects:• Headache• Hot flash• Hypercholesterolemia• Weight gain• Edema• ↓ bone density (long term in women)
38
Pavlovich et al. J Urol. 2001.
39
Testosterone:Estradiol Ratio
40
Pavlovich et al. J Urol 2001Pavlovich CP, King P et al. Evidence of treatable endocrinopathy in infertile men. J Urol 2001;165:837-841
Objective Assess serum T:E2 ratio in infertile and fertile men and the effect of testolactoneon semen parameters
Design Non-controlled trial
Inclusion Azoospermic or oligospermic men (n = 63) with clinical evidence of male factor infertility including:• Small testes• Increased serum FSH (mean: 21.2 ± 1.8 IU/L)• Abnormal semen analysisFertile men (n= 40)• Age matched• Proved fertility• No evidence of testicular dysfunction
Intervention (n=45) 50 – 100 mg oral testolactone twice daily for 5 months
T:E2 Ratio16
41
Outcome
Population characteristics
• Original population (n=63)• 43 azoospermic• 20 oligospermic
• Hormone analysis• 12 azoospermic• 12 oligospermic
Primary Outcomes • Hormonal evaluations: T, E2, T:E2, FSH, LH• Seminal parameters
Secondary Outcomes • Liver function testsT:E2 ratio (p<0.01) Infertile men (n = 24) Fertile men
6.9 ± 0.6 14.5 ± 1.2 (95% CI 7.2-21.8)FSH (p<0.01) 21.2 ± 1.8IU/L 5.5 ± 0.3 IU/L
T:E2 Ratio16
42
Outcome Baseline Post Intervention P value
T (ng/dL) 303 396 <0.01
E2 (ng/L) 66 37 <0.01
T:E2 ratio 5.0 ± 0.3 12.7 ± 1.2 <0.01
Sperm motility 27.1 ± 5.9% 45.3 ± 5.8 <0.01
Sperm concentration (million/mL) 16.1 ± 5.3 28.9 ± 8.3 0.03
Semen volume (million/ejaculate) 20.1 ± 8.8 54.1 ± 23.9 0.08
LFTs • Mild ↑ transaminase in 6 patients• Indirect bilirubinemia in 2 patients• None more than 2 fold above normal
Author’s Conclusion:Aromatase inhibitors can improve semen parameters and increase the T:E2 ratios
10/27/2017
8
T:E2 Ratio16
43
Strengths• T:E2 ratios not previously studied
Weaknesses• Small group, only 12 oligospermic
patients analyzed• No baseline characteristics• Varying etiologies, no exclusions• Non-randomized or controlled• Use testolactone• Single semen analyses• Possibility of sex hormone binding
globulin decrease• No side effect data reported
T:E2 Ratio16
44
• An aromatase inhibitor can normalize the T:E2 ratio in men and may have an effect on semen parameters in oligospermic men
Overall conclusion
• What is the normal T:E2 ratio in men?• Do aromatase inhibitors affect SHBG levels?• Can the nonsteroidal aromatase inhibitors affect male
semen parameters and male infertility in men with decreased T:E2 ratios?
Questions remaining
Saylam B, et al. Fertil Steril. 2011.
45
Letrozole and ↓T:E2Saylam B, Efesoy O, and Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril 2011;95:809-811.Objective • To investigate the effect of letrozole in BMI, serum hormones, and sperm
parameters in male infertility associated with ↓T:E2 ratiosDesign • Turkey
• Noncontrolled comparative trialInclusion • Infertile men with low T:E2 ratio (<10) (n=27)
• T < 330 ng/dLExclusion • Additional etiology (varicocele, ejaculatory duct obstruction)
• Female factor infertilityIntervention • All treated with 2.5 mg letrozole daily for ≥ 6 months
46
Letrozole and ↓T:E217
Outcome
Population characteristics
• Mean age 34.92 ± 6.66 (range: 26-49)• 17 azoospermic• 10 oligospermic
Primary outcome • Serum hormones: FSH, LH, T, E2, T:E2• BMI• Sperm parameters
Secondary outcomes • LFTs
47
Letrozole and ↓T:E217Outcomes: all patients Baseline Post-intervention P value
BMI (kg/m2) 28.40 ± 3.86 28.90 ± 4.43 0.288
Testicular volume (mL) 15.39 ± 4.49 15.56 ± 4.47 0.213
Total motile sperm (million) 2.37 ± 1.14 6.76 ± 2.37 0.009
Motility (%) 7.03 ± 2.33 12.96 ± 2.91 0.017
Sperm count (million) 3.04 ± 1.18 7.00 ± 2.01 0.002
Ejaculate volume (mL) 2.55 ± 0.17 3.18 ± 0.19 0.001
FSH (mIU/mL) 9.16 ± 1.95 9.30 ± 1.94 0.360
LH (mIU/mL) 10.29 ±1.62 10.14 ± 1.60 0.117
T (ng/dL) 255 ± 23 527 ± 74 0.001
E2 (pg/mL) 25.93 ± 1.97 14.68 ± 2.01 0.001
T:E2 ratio 8 ± 0.4 39 ± 6.1 0.001
48
10/27/2017
9
Letrozole and ↓T:E217
Outcomes: Oligospermic Baseline (n=10) Post-intervention (n=10) P value
Total motile sperm (million) 6.41 ± 2.72 15.77 ± 5.01 0.016
Motility (%) 19.00 ± 4.13 24.00 ± 3.31 0.017
Sperm count (million) 8.12 ± 2.48 17.00 ± 3.56 0.03
Ejaculate volume (mL) 2.62 ± 0.22 3.59 ± 0.31 0.031
Pregnancy 0 2 --
49
Outcomes: Azoospermic Baseline (n=17) Post-intervention (n=4) P value
Total motile sperm (million) 0 1.46 ± 1.23 0.253
Motility (%) 0 6.47 ± 3.34 0.071
Sperm count (million) 0 1.11 ± 0.69 0.125
Ejaculate volume (mL) 2.51 ± 0.24 2.94 ± 0.23 0.007
Letrozole Side Effects17
50
No severe side effects observed
Mild headache
(n=2)Author’s Conclusion: Letrozole may be used to effectively improve sperm parameters in infertile men with low serum T:E2 ratio and may lead to pregnancy, and may improve sperm count in azoospermia.
51
Strengths• First study involving
letrozole• Excluded patients with
other etiology• Reported side effects• Reported pregnancies• Multiple samples
Weaknesses• Small groups• Non-randomized or
controlled
Letrozole and ↓T:E217 Letrozole and ↓T:E217
52
• Letrozole may safely help improve sperm parameters in oligospermic men with ↓T:E2 in order to improve fertility and pregnancy rate
• Letrozole is well tolerated
Overall conclusion
• Should T:E2 <10 be the standardized cut-off?• Can anastrozole have similar effects?
Questions remaining
Shoshany et al.Fertil Steril. 2017.
53
Anastrozole and ↓T:E211
Shoshany O, Abhyankar N, et al. Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertilemen. Fertil Steril. 2017;107(3):589-594.Objective • To assess whether anastrozole can affect the sperm parameters in subfertile
hypoandrogenic men with ↓T:E2Design • Retrospective study
• Male fertility clinicInclusion • Hypoandrogenic subfertile men (n=86)
• Low T: <155 ng/dL• Either: low T:E2 <10 (n=78) or adverse reaction to clomiphene citrate (n=8)
Exclusion • History of sex chromosomal disorder• Past exogenous T use• Other concomitant hormonal treatment
Intervention • Anastrozole 1 mg daily for 4 months
54
10/27/2017
10
Anastrozole and ↓T:E211
Outcome
Population characteristics
• Median age: 37 (range: 32-41)• Mean duration of unprotected intercourse: 24 months (18-48)• 50 oligospermic• 28 azoospermic• 8 cryptozoospermic
Outcomes • Hormone analysis: total T, bioavailable T, E2, SHBG, albumin , FSH, LH• Semen analysis
55
Anastrozole and ↓T:E211
Outcome Baseline 3 week 4 month P value
Total T (ng/dL) 258.4 ± 10.8 509.2 ± 20.4 449.4 ± 19.5 <0.0001
Bioavailable T (ng/dL) 128.8 ± 4.7 297.5 ± 12.7 -- <0.0001
E2 (pg/mL) 40.8 ± 1.9 24.6 ± 2.1 23.2 ± 2.2 <0.0001
T:E2 6.98 ± 0.33 34.5 ± 6.5 24.2 ± 3 <0.0001
SHBG (nmol/L) 25.6 ± 1.1 24.9 ± 1.2 -- Not significant
LH (IU/L) 6.41 ± 0.89 10.7 ± 1.1 -- <0.0001
FSH (IU/L) 12.4 ± 2 19.4 ± 2.3 -- <0.0001
56
Anastrozole and ↓T:E211
Outcome Baseline 3 week 4 month P valueVolume (mL) 2.56 ± 0.22 -- 2.32 ± 0.25 NS
Concentration (million/mL) 4.7 ± 1.2 -- 13.1 ± 2.9 0.001
Motility (%) 39.9 ± 5 -- 40.5 ± 4.8 NS
Total motile count (million) 4.6 ± 1.3 -- 8 ± 3.4 <0.01
57
• In oligospermic men only (n = 21)• Total motile count correlated with ↑T:E2 (P<0.0001)
• Controlled for Age and FSH concentration• Did not correlate to any other outcome
Anastrozole Side Effects11
58
Bilateral ankle swelling, resolved with continued
treatment (n = 1)
Decreased libido, irritability, depression, bilateral breast
tenderness,ocular pruritus/pain, and
dry mouth (n = 1)
Paradoxical increase in E2 (n = 1)
Joint and tendon pain, and swelling in limbs
(n=2)
Author’s Conclusion: Anastrozole improved endocrine parameters in men with hypoandrogenism and sperm parameters in oligospermicmen. Total motile count correlated to ↑T:E2, thus arguing for a physiologic effect of treatment.
59
Strengths• Excluded patients with
other etiology• Side effects reported• 2 semen samples per
patient• Evaluated SHBG levels
Weaknesses• Retrospective,
noncontrolled• Small group for seminal
parameters• Varicocele etiology• Did not report pregnancy
Anastrozole and ↓T:E211 Anastrozole and ↓T:E211
60
• Anastrozole may help improve endocrinopathy and seminal parameters in oligospermic men.
• Anastrozole is well toleratedOverall
conclusion• Which is more effective, anastrazole or letrozole,
improving seminal parameters and infertility?• Which is better tolerated?• Can aromatase inhibitors improve sperm retrieval in
azoospermic men?
Questions remaining
10/27/2017
11
Gregoriou et al. Fertil Steril. 2012.
61
Anastrozole vs LetrozoleGregoriou O, Bakas P, et al. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril. 2012;98(1):48-51Objective • To compare the effects of 2.5 mg letrozole with those of 1 mg anastrozole daily
Design • Prospective, nonrandomized study
Inclusion • Infertile men (n=29) • T:E2 <10• T<300
Exclusion • Abnormal karyotype analysis• Y chromosome microdeletion
Intervention • 2.5 mg letrozole daily for 6 months (n=15)• 1 mg anastrozole daily for 6 months (n=14)
62
Anastrozole vs Letrozole18
Outcome
Baseline population • None reported
Primary outcomes • Serum hormones: FSH, LH, T, E2• Seminal analysis
Secondary outcomes • Liver function tests monthly
63
Letrozole18Outcome Pre-intervention Post-intervention P value
BMI (kg/m2) 29.86 ± 2.53 30.1 ± 2.13 >0.05
Testicular volume (mL) 14.89 ± 4.32 15.01 ± 4.30 0.94
FSH (mIU/mL) 8.35 ± 2.03 8.41 ± 1.95 0.93
LH (mIU/mL) 9.55 ± 1.84 9.28 ± 1.80 0.69
T (ng/dL) 275 ± 29 495 ± 65 <0.001
E2 (pg/mL) 26.7 ± 1.75 14.98 ± 2.58 <0.001
T:E2 ratio 9 ± 0.2 36 ± 4.5 <0.001
Ejaculate Volume (mL) 2.85 ± 0.36 3.35 ± 0.2 0.005
Sperm count (million) 3.5 ± 1.43 5.19 ± 1.62 0.001
Motility (%) 11.05 ± 2.48 22.13 ± 4.37 0.001
Total functional sperm fraction (million)
1.71 ± 0.87 2.51 ± 1.09 0.013
64
Anastrozole18Outcome Pre-intervention Post-intervention P value
BMI (kg/m2) 30.14 ± 3.1 30.0 ± 2.75 >0.05
Testicular volume (mL) 13.65 ± 3.95 13.89 ± 3.42 0.86
FSH (mIU/mL) 8.35 ± 1.95 8.45 ± 1.93 0.89
LH (mIU/mL) 11.15 ± 1.58 11.01 ± 1.53 0.81
T (ng/dL) 265 ± 25 513 ± 65 <0.001
E2 (pg/mL) 24.1 ± 20.1 15.15 ± 1.95 <0.001
T:E2 ratio 8 ± 0.5 34 ± 5.9 <0.001
Ejaculate Volume (mL) 2.40 ± 0.15 3.18 ± 0.52 <0.001
Sperm count (million) 4.15 ± 3.38 8.9 ± 2.11 <0.001
Motility (%) 12.35 ± 3.89 22.85 ± 3.38 <0.001
Total functional sperm fraction (million)
1.91 ± 1.25 2.41 ± 1.06 0.005
65
Letrozole and Anastrazole Side Effects18
66
Letrozole↑ liver
enzymes (n=1)
Transient weakness
(n=2)
Nausea x 10 days
(n=1)
Mild headache
(n=2)
Anastrazole↑ liver
enzymes (n=2)
Mild diarrhea x 3 days (n=1)
Transient nausea (n=2)
Mild headache
(n=1)
Author’s Conclusion:Anastrozole and letrozole are equally effective in improving T levels and seminal parameters in men with severe oligospermia, low T levels, and normal gonadotropins.
10/27/2017
12
67
Strengths• Compared letrozole and
anastrozole• 2 semen samples per patient• Reported side effects• All patients were oligospermic
Weaknesses• Small groups• No baseline characteristics
reported• Not randomized or controlled• Not powered to detect
statistical significance between the two differences
• Pregnancies not reported
Anastrozole vs Letrozole18
68
• Aromatase inhibitors may help improve seminal parameters and endocrinopathy in oligospermic men with low T:E2 ratios.
• Both aromatase inhibitors seem well tolerated
Overall conclusion
• Are anastrazole and letrozole equally effective, in improving seminal parameters and infertility?
• Is one better tolerated than the other?
Questions remaining
Anastrozole vs Letrozole18
Literature Summary
69
Summary of Literature11,16-18
Study Pavlovich et al. Saylam et al. Shoshany et al. Gregoriou et al.
Design Prospective Prospective Retrospective Prospective
Drug Testolactone Letrozole Anastrozole Letrozole Anastrozole
Dose 50 – 100 mg daily 2.5 mg daily 1 mg daily 2.5 mg daily 1 mg daily
Duration 5 months ≥ 6 months 4 months 6 months
Patients N = 63;24 N=27 N=86;21 N=15 N=14
Diagnosis Oligospermic, azoospermic
Oligospermic, azoospermic
Oligospermic, azoospermic, cryptozoospermic
Oligospermic
# semen samples 1 3 2 2
Side effects reported
No Yes Yes Yes
70
Summary of Literature11,16-18Outcome Pavlovich et al. Saylam et al. Shoshany et al. Gregoriou et al. Drug Testolactone Letrozole Anastrozole Letrozole AnastrozoleBMI -- NS -- NS NSTesticular volume -- NS -- NS NSFSH -- NS ↑ NS NSLH NS NS ↑ NS NST ↑ ↑ ↑ ↑ ↑ E2 ↓ ↓ ↓ ↓ ↓T:E2 ratio ↑ ↑ ↑ ↑ ↑Ejaculate volume NS ↑ NS ↑ ↑Sperm count ↑ ↑ ↑ ↑ ↑Motility ↑ ↑ NS* ↑ ↑SHBG -- -- NS -- --TFSF -- -- -- ↑ ↑
71APPENDIX F *↑total motile count
Aromatase inhibitors2,3,5,13-15
•Pros:• ↑ T without ↑ E2• ↑ T:E2 ratio• Inexpensive
•Cons:• Less evidence• No consistent regimen
•Clinical use: • Hypogonadism with low T:E2 ratio (<10)
72
10/27/2017
13
APPENDIX E 73
hCG
Rambhatla et al. Urol. 2016
Knowledge CheckMultiple Choice:Which of the following medications has an FDA indication for male hypogonadism? [Select all that apply]A. ClomipheneB. AnastrozoleC. hCGD. Testosterone
74
Knowledge checkMultiple choiceAromatase inhibitors may increase the following parameters except:A. Sperm countB. Testicular volumeC. Testosterone:Estradiol ratioD. Testosterone
75
Treatment algorithm
Mal
e in
fert
ility
and
hy
pogo
nadi
sm
T:E2 <10 or increased E2 levels?
Yes Anastrozole
Failed treatment Human chorionic gonadotropin
No ClomipheneFailed treatment Human chorionic
gonadotropin
76
Conclusion•T:E2 ratio seems to be correlated with infertility in some oligospermic infertile men•T:E2 < 10 should be used as a guide •Aromatase inhibitors may help oligospermic men• ↑ T • ↓ E2• ↑ T:E2• ↑ sperm count• ↑ sperm motility
77
Future research•Prospective randomized trials•Normal/optimal T:E2 ratio•Different dosing schedules• 2-3 times weekly vs daily
•Aromatase inhibitors and sperm retrieval in azoospermic men•Tolerability and long term effects• Bone density• Hypercholesterolemia
•Guideline implementation
78
10/27/2017
14
Acknowledgments•Evaluator• Sharon Rush, R.Ph.
•Residency Program Director• Nathan Pope, Pharm.D., BCACP,
FACA
•Preceptors• James Weems, R.Ph.• Amanda Stallings, Pharm.D.• Gretta Leckbee, R.Ph.• Jennifer Wilbanks, R.Ph.• Lauren Clark, Pharm.D.• Mark Comfort, Pharm.D.
79
Questions?
Aromatase Inhibitors in Male Infertility: The hype of hypogonadism?BEATRIZ UGALDE, PHARM.D.
H-E-B/UNIVERSITY OF TEXAS COMMUNITY PHARMACY PGY1
03 NOVEMBER 2017
PHARMACOTHERAPY ROUNDS